Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage



Status:Recruiting
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - 89
Updated:1/31/2019
Start Date:January 2016
End Date:August 2019
Contact:Edward T Van matre, PharmD
Email:edward.vanmatre@ucdenver.edu

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
This study evaluates the pharmacokinetic profile of levetiracetam in critically ill patients
who have suffered a subarachnoid hemorrhage. The patients will be evaluated for development
of augmented renal clearance and the effects and duration of effects this may have on
levetiracetam clearance.


Inclusion Criteria:

- Patients diagnosed with non-traumatic subarachnoid hemorrhage requiring levetiracetam
for seizure prophylaxis or treatment

- Presentation to University of Colorado Hospital within 48 hours of subarachnoid
hemorrhage

- Adults ages 18 to 89 years

- Anticipated length of stay ≥ 48 hours

- Informed consent provided by the patient or patient's designated medical proxy

Exclusion Criteria:

- Pregnancy

- Patients receiving renal replacement therapy

- Brain death or imminent brain death expected ≤48 hours

- Patient with history of nephrectomy or renal transplant
We found this trial at
1
site
University of Colorado Hospital
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
Phone: 720-848-6964
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials